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Abstract
Objectives: To aid the development of treatment for cognitive impairment in bipolar 
disorder, the International Society for Bipolar Disorders (ISBD) convened a task force 
to create a consensus- based guidance paper for the methodology and design of cogni-
tion trials in bipolar disorder.
Methods: The task force was launched in September 2016, consisting of 18 interna-
tional experts from nine countries. A series of methodological issues were identified 
based on literature review and expert opinion. The issues were discussed and ex-
panded upon in an initial face- to- face meeting, telephone conference call and email 
exchanges. Based upon these exchanges, recommendations were achieved.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | INTRODUCTION
There is a pressing need for treatments targeting cognitive impair-
ments in bipolar disorder to enhance functional recovery and reduce 
societal costs.1 Specifically, cognitive impairments in sustained atten-
tion, verbal memory and executive function often persist after clinical 
remission from mood episodes 2,3 and may be influenced further by 
mood- stabilizing and antipsychotic treatments.4,5 Emerging evidence 
points to cognitive heterogeneity in the remitted phase of bipolar dis-
order, with 12%- 40% of patients displaying global cognitive deficits, 
29%- 40% showing selective decline in attention and psychomotor 
speed, and 32%- 48% being relatively cognitively intact.6-8 Notably, 
the subgroups with neurocognitive impairments present reduced 
functional capacity, more stress and poorer quality of life than patients 
who are cognitively intact, despite similar degrees of subsyndromal 
mood symptoms.7,8 This highlights a need to target cognition treat-
ments specifically to the cognitively impaired subgroups.
There is, however, a lack of clinically available effective treatments 
for cognitive impairments in bipolar disorder. This is partially a result 
of major methodological challenges in this relatively new field, as high-
lighted in a previous systematic review of clinical studies of candidate 
cognition treatments in bipolar disorder1 and a recent expert opinion 
paper.9 In particular, the review noted that the majority of trials used 
no systematic pre- screening for cognitive impairment. Further, criteria 
used for selecting trial participants, tests used for assessing treatment 
efficacy on cognition, allowance of non- study medications, and sta-
tistical procedures differed between the studies.1,9 Such broad meth-
odological discrepancies provide the impetus for greater consensus 
in the field, on the design and methodology of cognition trials in bi-
polar disorder, to optimize the chances of demonstrating treatment 
efficacy on cognition and to aid comparability across trials. In addi-
tion, a key challenge in the clinical management of bipolar disorder 
is the absence of recommendations for physicians on how to assess 
and manage cognitive impairments in their patients. The International 
Society for Bipolar Disorders (ISBD) therefore convened an expert task 
force under the lead of Dr Miskowiak with the aim of developing (i) a 
consensus- based guidance paper for the methodology and design of 
cognition trials in bipolar disorder for pharmacological as well as non- 
pharmacological interventions, (ii) a clinical recommendations paper 
for physicians on how to address cognitive impairments in their pa-
tients, and (iii) an educational patient booklet with information about 
cognitive impairments and pragmatic strategies for compensating for 
these in daily life.
This specific paper addresses goal (i). As the field is at an early stage 
in its development, defining a set of fixed guidelines for cognition tri-
als would be premature; the aim of the present paper is instead to 
provide consensus- based guidance and recommendations from inter-
national experts in the field that can support decisions regarding the 
methodology and design of future cognition trials in bipolar disorder. 
While the task force recommendations are primarily intended for ran-
domized controlled cognition trials, the principles can also be applied 
to naturalistic or quasi- experimental studies. These consensus- based 
methodological recommendations build on insights from a recent sys-
tematic review of trials targeting cognition in bipolar disorder1 and an 
expert opinion paper,9 which were reviewed, discussed and expanded 
on by members of this ISBD task force.
Results: Key methodological challenges are: lack of consensus on how to screen for 
entry into cognitive treatment trials, define cognitive impairment, track efficacy, assess 
functional implications, and manage mood symptoms and concomitant medication. 
Task force recommendations are to: (i) enrich trials with objectively measured cogni-
tively impaired patients; (ii) generally select a broad cognitive composite score as the 
primary outcome and a functional measure as a key secondary outcome; and (iii) in-
clude remitted or partly remitted patients. It is strongly encouraged that trials exclude 
patients with current substance or alcohol use disorders, neurological disease or unsta-
ble medical illness, and keep non- study medications stable. Additional methodological 
considerations include neuroimaging assessments, targeting of treatments to illness 
stage and using a multimodal approach.
Conclusions: This ISBD task force guidance paper provides the first consensus- based 
recommendations for cognition trials in bipolar disorder. Adherence to these recom-
mendations will likely improve the sensitivity in detecting treatment efficacy in future 
trials and increase comparability between studies.
K E Y W O R D S
bipolar disorder, cognitive impairment, methodology, recommendations, treatment
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2  | MATERIALS AND METHODS
2.1 | The ISBD Targeting Cognition Task Force
The ISBD Targeting Cognition Task Force was initiated by Drs 
Miskowiak, Kessing, and Vieta and consisted of 18 international 
experts in cognition in affective disorders from the following nine 
countries (in alphabetical order): Brazil, Canada, Colombia, Denmark, 
Japan, New Zealand, Spain, the UK, and the USA. The members of 
the ISBD Targeting Cognition Task Force were selected based upon 
their expertise in cognition in bipolar disorder and include sev-
eral members of a previous ISBD Cognition Task Force led by Dr 
Yatham.10
2.2 | The process of the task force
A series of major methodological challenges in the field were identi-
fied from a recent systematic review of cognition trials in bipolar disor-
der1 and a methodological expert opinion paper on the assessment of 
cognition in this patient group.9 An introductory face- to- face meeting 
was then held at the European College of Neuropsychopharmacology 
(ECNP) annual congress (Vienna, September 2016), during which the 
overall work timelines for accomplishing the goals were discussed, 
a tentative list with the key methodological issues in cognition trials 
was reviewed and agreed upon, and possible solutions to the issues 
were discussed. This was followed up by a telephone conference 
with the members of the task force who were unable to attend the 
introductory meeting. During the call, the identified methodological 
challenges and possible solutions were discussed and agreed upon, 
and additional challenges were added to the list. Consensus on the 
methodological challenges and recommendations with regard to how 
these challenges may be tackled was reached through subsequent 
email exchanges. Any differences in opinion between task force mem-
bers were resolved in all cases through a telephone call between the 
particular task force members and the task force chair (Dr Miskowiak). 
The use of formal consensus methods such as the Delphi method was 
deemed unnecessary given a high degree of agreement among the 
members of the task force.
3  | RESULTS
3.1 | How can we enrich trials with cognitively 
impaired patients?
One- third to half of patients with bipolar disorder do not show clini-
cally relevant objectively measured cognitive impairments during 
remission. A major reason for the overall lack of progress in develop-
ment of new treatments for cognitive impairment in bipolar disorder 
may have to do with the fact that most (80%) cognition trials do not 
pre- screen patients for cognitive impairment, thus including a per-
centage of cognitively intact patients, which affects signal detection.1 
The task force therefore considers it critical in randomized controlled 
trials (RCTs) to pre- screen patients for cognitive impairment. This will 
increase statistical power and thus the likelihood of signal detection, 
minimize the risk of unnecessary exposure of cognitively intact pa-
tients to novel investigational treatments, reduce treatment develop-
ment costs, and result in a shorter time to bring novel treatments to 
patients with cognitive deficits.
Among the 20% (n = 23) of cognition trials in bipolar disorder that 
did include pre- screening for cognitive impairment, a vast majority 
used subjectively self- reported rather than objective neuropsycholog-
ical screening tools.1 Since up to half of remitted patients are objec-
tively cognitively intact despite subjective cognitive complaints,6,7 this 
can lead to enrollment of patients with little or no scope for cognitive 
improvement and thus a high risk of type II errors.11-13 Indeed, recent 
evidence from several cognition trials suggests that patients with 
objectively assessed cognitive impairment have substantially greater 
chances of achieving treatment efficacy on cognition than those who 
are non- impaired.11,12,14-16 While subjectively perceived cognitive 
difficulties may also increase the likelihood of treatment efficacy on 
cognition, this association is weak14 and not consistently observed.15 
It therefore seems insufficient to rely only on patients’ subjectively 
reported cognitive difficulties, although these are arguably important 
for patient participation in trials and for clinical meaningfulness of 
cognition treatments. Indeed, the correlation between subjective and 
objective measures of cognition is poor,17,18 indicating that it is not 
always the patients with most subjective complaints who show great-
est objective deficits and vice versa. This discrepancy seems to be in-
fluenced by patients’ clinical characteristics, with disproportionately 
more subjective than objective cognitive impairment in patients with 
greater subsyndromal depression or mania symptom severity, bipolar 
disorder type II (vs type I), and greater illness chronicity.19
Given the poor correlation between subjective and objective cog-
nition measures and some evidence for greater treatment benefits in 
objectively impaired patients, it seems reasonable to enrich for ob-
jective cognitive impairment in future trials to achieve more positive 
outcomes of RCTs that utilize objective primary outcome measures. 
Subjective cognitive impairment is also important to ensure that the 
treatment is meaningful and that patients comply with trial require-
ments. However, some patients are unaware of their deficits and do 
not report them, but may nevertheless experience difficulties with 
retaining normal functioning at work and in daily life due to their cog-
nitive impairments.20 Given this, it would be advisable to enroll pa-
tients that present with both (i) subjective cognitive difficulties and/
or socio- occupation problems and (ii) objectively measured cognitive 
deficits. For efficiency purposes, a sequential screening process may 
be considered. First, a large number of patients could be given easy- 
to- administer subjective measures (questionnaires) to pre- screen for 
cognitive complaints and socio- occupational problems. This will aid 
recruitment and retaining of participants in the trial. Second, patients 
with self- reported cognitive complaints and/or socio- occupational dif-
ficulties can then be assessed with an objective tool (i.e., brief neuro-
psychological test) to substantiate that they also display measurable 
cognitive deficits and thus ensure indication enrichment.
Several self- report and neuropsychological measures may be im-
plemented in this screening process. Two new screening tools with 
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documented sensitivity to cognitive impairment in bipolar disorder 
may be particularly feasible: (i) the self- report measure Cognitive 
Complaints in Bipolar Disorder Rating Assessment (COBRA),21 for as-
sessment of subjective impairment, and (ii) the brief neuropsycholog-
ical tool Screen for Cognitive Impairment in Psychiatry (SCIP),22 for 
detection of objective cognitive impairment. An alternative approach 
to screen for objective cognitive impairment is to use two single neu-
ropsychological tests that tap into different cognitive domains, such as 
verbal memory and executive function.16 The COBRA has been devel-
oped for bipolar disorder21; using a cut- off of >14 on this scale—which 
indicates moderate to severe self- reported difficulties—provides ade-
quate specificity (74%) but somewhat suboptimal sensitivity (68%) for 
objective cognitive impairments. The optimal cut- offs on the SCIP for 
cognitive impairment have been investigated in several studies.18,23,24 
In the context of pre- screening patients for cognition trials, we suggest 
a SCIP cut- off of <75 (for details, see section 3.2).
3.2 | What is a reasonable threshold for cognitive 
impairment?
There is no consensus definition of “clinically significant” cognitive 
impairment in terms of standard deviations (SDs) for neuropsycho-
logical test performance from the mean of a normative group.25 These 
definitions therefore vary across studies of neuropsychiatric patients, 
with some using a cut- off corresponding to performance scores ≥2 SD 
below the normative mean, and others using less conservative cut- offs 
of ≥1.5 or ≥1 SD under the norm.25-27 It is also unclear whether such 
thresholds should be based on single or several neuropsychological 
tests.25 Notably, it is relatively common that cognitively intact peo-
ple, defined by their overall composite score, perform 1 SD under the 
norm on a single neuropsychological test.25 It thus seems necessary to 
apply such a cognitive impairment threshold to two or more cognitive 
tests. In a secondary analysis of data from the erythropoietin (EPO) 
trials, participants with a score of ≥1 SD below the norm on at least 
two cognitive tests had substantially greater chances of treatment ef-
ficacy than unimpaired individuals.15 Notably, this did not represent 
simple regression towards the mean, since such influence of baseline 
deficits was not observed in the placebo group.15 However, application 
of a threshold of ≥1 SD for cognitive impairment to a global cognition 
measure based on a broad neuropsychological assessment is likely to 
be too conservative, since only 12%- 40% patients display global im-
pairments.6-8 It would therefore be advisable to employ a less conserv-
ative threshold on a global cognition measure, such as performance 
≥0.5 SD below the norm. Indeed, it has been shown in a receiving 
operator characteristic (ROC) analysis of the SCIP that using a cut- off 
of <75—corresponding to ≥0.5 SD under the mean of healthy age- 
matched controls—provides adequate sensitivity and specificity (81% 
and 76%, respectively) for detection of cognitive impairments in bipo-
lar disorder.18 Nevertheless, the selection of a cut- off should be based 
on a balance between the desired specificity for cognitive impairment 
and practical recruitment considerations in the individual trial. While 
a high cut- off optimizes specificity and increases statistical power, it 
limits inclusion of trial participants and generalizability of the findings.
3.3 | Why is consideration of cognitive reserve 
important?
If logistically feasible, it may be worth establishing cognitive impairment 
with reference to patients’ premorbid cognitive reserve, as reflected 
by their premorbid IQ, educational level and occupational attain-
ment.28 Cognitive reserve reflects the capacity of the brain to tolerate 
neuropathology, minimize symptom manifestations and slow down 
the clinical presentation of neurocognitive decline.29,30 Consideration 
of cognitive reserve is relevant since neuropsychological tests alone 
may be less sensitive to cognitive change in patients with substantial 
above- normal premorbid function. Useful IQ or premorbid IQ tests in-
clude the National Adult Reading Test (or locally equivalent tests), the 
Advanced Clinical Solutions (ACS) Test of Premorbid Functioning, the 
Wide Range Achievement Reading Recognition Test and the 2- subtest 
IQ from the Wechsler Abbreviated Scale of Intelligence. Educational 
attainment may be a suboptimal measure of premorbid cognitive re-
serve and for matching patients and controls, since patients with bipo-
lar disorder tend to complete fewer years of education than controls 
despite comparable IQ levels.31 Obtaining estimates of premorbid IQ 
would also enable detection of participants with intellectual disabil-
ity (i.e., IQ < 70- 75) whose poor cognitive performance is unlikely to 
represent illness- associated impairment and thus be more resistant to 
cognitive- enhancing treatments. Such assessments could inform deci-
sions on (i) whether individuals with remarkably high cognitive reserve 
but only small impairments (in comparison with norms) should be al-
lowed in the trial and (ii) whether individuals with very low cognitive 
reserve (e.g., IQ < 80) should be excluded as in recent studies.13,32
3.4 | Which criteria should be used to select trial 
participants?
There is great disparity in the inclusion and exclusion criteria across 
RCTs targeting cognition in bipolar disorder. The task force therefore 
carefully evaluated inclusion and exclusion criteria for cognition trials, 
taking into account study validity, generalizability, chances for signal 
detection, and recruitment feasibility. In addition to improving indica-
tion enrichment by screening for objective cognitive impairment, the 
following recommendations may also significantly aid the methodol-
ogy of future trials.
A particular challenge for cognition trials in bipolar disorder is the 
influence of mania and depression symptoms, and their episodic na-
ture, on cognitive function.33 Recommendations on whether or not to 
allow for mood symptoms depend on the particular study aim and type 
of treatment under investigation. For trials with cognition as a primary 
outcome, patients should generally be partially remitted or euthymic, 
depending on the profile of the drug effects. Specifically, trials investi-
gating candidate treatments with no known efficacy on mood should 
allow for subsyndromal symptoms in the interest of recruitment fea-
sibility and generalizability of the results, since persistent subsyndro-
mal symptoms (particularly of depression) are common in periods of 
mood stability. In contrast, trials investigating medications with well- 
documented effects on mood should preferentially include euthymic 
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patients to rule out “pseudo- specificity” (i.e., nonspecific cognitive 
improvement due to treatment- related decrease in mood symptoms). 
We propose euthymia defined as Hamilton Depression Rating Scale 
(HDRS) or Montgomery–Åsberg Depression Rating Scale (MADRS) 
and Young Mania Rating Scale (YMRS) scores ≤7. Some studies have 
included prospective verification of euthymia, where patients are mon-
itored for up to 1 month prior to assessment.34,35 If such an approach 
is logistically feasible, it offers a more rigorous method of ensuring 
the euthymic period is stable. However, it should be noted that the 
proposed distinction in inclusion criteria between euthymic and partly 
remitted patients may be somewhat artificial, since patients who are 
euthymic at inclusion may develop mood symptoms during the trial 
period. Further, euthymic patients included in a study of drugs with 
known antidepressant effects could run a higher risk of switching to 
mania than patients with subsyndromal depressive symptoms. Finally, 
for trials with mood symptoms as the primary outcome and cognition 
as a secondary outcome, patients will be presenting with moderate 
to severe mood symptoms. In these trials, potential treatment- related 
cognitive improvement can provide only preliminary evidence for ef-
ficacy on cognition and necessitates replication in a study with cogni-
tion as the primary outcome.
Concomitant medications are a confounder in cognition trials 
due to their effects on cognition but must be allowed for ethical and 
clinical reasons to maintain mood stability and to ensure the repre-
sentativeness of the patient sample (and thus generalizability of the 
findings). The cognitive side effects of commonly prescribed med-
ications for mood symptoms and anxiety are not fully elucidated. 
Nevertheless, benzodiazepines as well as some antipsychotics, mood 
stabilizers and antidepressants have documented cognitive side ef-
fects, partially due to their anti- histaminergic, anti- dopaminergic, 
and anticholinergic actions.4,5 It is therefore advisable to avoid high 
doses of concomitant antipsychotics and anticholinergic medications 
whenever possible. Decreasing doses of medication should never-
theless be traded off against the risk of relapse of mood symptoms, 
which may invalidate results of the trial. It would also be advisable to 
taper benzodiazepines to a maximum dose equivalent to ≤22.5 mg 
oxazepam or ≤7.5 mg diazepam per day (cut- offs for doses with es-
timated limited cognitive side effects) and to restrict use of benzo-
diazepine and other hypnotics for at least 6 hours prior to cognitive 
testing. Serum lithium dose should be monitored and be kept within 
the therapeutic range throughout the trial to avoid confounding cog-
nitive side effects of lithium toxicity. In general, patients should be on 
stable medication for at least 2- 6 weeks before trial start, depending 
on whether the treatment change is merely a dose adjustment or 
commencement of a new treatment. Concomitant medication should 
be carefully recorded and, if possible, kept stable throughout trial 
participation. If a candidate treatment is found to improve cognition, 
post hoc analysis should include adjustment for concomitant medi-
cations to determine whether the significant effects prevail (and are 
thus independent of non- study medication). Finally, electroconvul-
sive therapy (ECT) in the past 6 months should be an exclusion cri-
terion since cognitive impairments may in such cases be ECT- rather 
than illness- associated.
There is a need for consensus on how to tackle medical and psy-
chiatric comorbidity in cognition trials. In general, patients should be 
excluded if they have a history of moderate or more severe brain injury, 
neurological disease, current uncontrolled thyroid condition, unstable 
medical illness, current or recent (i.e., within the past 1- 3 months) 
alcohol and substance use disorders, or intellectual disability, since 
these are likely to hamper the chances of treatment efficacy on cog-
nition. Patients should also be excluded if they have a current comor-
bid diagnosis of attention deficit hyperactivity disorder verified during 
the diagnostic screening interview, since the investigational treatment 
aims target cognitive deficits associated more specifically with bipolar 
disorder. Comorbid anxiety and sleep disorders may exacerbate pa-
tients’ cognitive impairment. However, they should not be exclusion 
criteria since this would impede recruitment and generalizability, given 
the high comorbidity between bipolar disorder and anxiety disorders 
36 and high rates of circadian rhythm disturbance and abnormal sleep 
in bipolar disorder.37 However, careful recording of anxiety symptoms 
and sleep quality during the trial is advisable as this enables investi-
gation of their potential influence on treatment effects on cognition 
in exploratory post hoc analyses. Finally, patients recruited into cog-
nition trials should have mastery of the language in which the neuro-
psychological tests are validated/administered, as this is necessary for 
obtaining valid cognitive assessments during the trial.
3.5 | How should efficacy on cognition be assessed?
There is a lack of consensus on which cognition measures to de-
fine as primary outcomes and on a priori hierarchy between cogni-
tion measures in most trials in bipolar disorder.1 In some instances, 
the choice of the cognitive outcome measure may be driven by the 
specific brain or cognitive mechanisms that might be targeted by a 
particular agent or treatment under study. For example, if an agent 
is proposed to act on a neurotransmitter or neural system that sub-
serves a specific cognitive ability, it may be desirable to select the 
primary cognitive outcome based on this demonstrated link between 
brain and behavior.38,39 In other instances, there may not be a clear 
specific cognitive target and therefore a key recommendation is to se-
lect one primary broad cognitive composite score spanning sustained 
attention, verbal memory, and executive functions that is sensitive to 
the cognitive deficits in bipolar disorder, such as the ISBD - Battery 
for Assessment of Neurocognition (ISBD- BANC) composite10 or the 
“speed of complex cognitive processing” composite15,40 which are im-
plemented in completed and ongoing cognition trials (ClinicalTrial.gov 
ID: NCT01470781).15,16,40 Given the cognitive heterogeneity in bipo-
lar disorder, a broad cognitive composite score may—by summarizing 
the change across several domains—be a more robust outcome than 
a single cognition test as it can pick up small cumulative treatment ef-
fects across several cognitive domains.9 The recommended procedure 
for deriving such a common metric for cognition is to calculate the 
composite score as the mean of the individual component z- scores for 
attention, memory, and executive function tests standardized against 
a healthy normative sample of average intelligence. Ideally, the vari-
ous individual measures would have been co- normed, i.e., the norms 
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would have been collected from the same normative population, and 
demographic- corrected norms (e.g., age, IQ/education and gender) 
would be available. Alternative strategies may be considered if there 
is no available norm group for the particular tests, such as use of meta- 
norms, or calculating z- scores by referencing the scores to the study 
baseline or control group performance.
The use of a specific set of neuropsychological tests for the pri-
mary cognition outcome across all future cognition trials would 
maximize comparability between studies. However, the task force is 
mindful of the international research community and that not all coun-
tries have the exact tests of the ISBD- BANC or the “speed of complex 
cognitive processing” composites available. The task force therefore 
recommends that trials match the neuropsychological tests in their 
primary cognition outcome as closely as possible to the tests in the 
ISBD- BANC or “speed of complex cognitive processing” composites. 
Broadly equivalent tests probing attention, verbal memory and exec-
utive function would thus be adequate. While not developed for bi-
polar disorder, the MATRICS Consensus Cognitive Battery (MCCB) is 
translated into >50 languages and normed in many countries and it has 
been validated in bipolar disorder in several independent samples.41-43 
Given that the ISBD- BANC includes many of the MCCB subtests, 
there should be a reasonable ability for trials to include most tests 
of the ISBD- BANC. A degree of flexibility is also advisable in cases 
where prior studies have shown benefits of a compound on specific 
cognitive tests; in such cases, it would be meaningful to include these 
tests in the primary cognition outcome in subsequent replication trials. 
Important next steps that are prerequisites for developing consensus 
on a specific test battery would be: (i) a factor- analytic study of cogni-
tive impairments in bipolar disorder based on existing cognitive data 
sets, and (ii) validating the factor structure against external validators 
such as functional capacity.
Individual cognition outcomes of interest for bipolar disorder and 
for a particular candidate intervention should be included as second-
ary outcomes (together with a functional outcome/co- primary mea-
sure; see later). For example, social cognition (such as facial expression 
recognition) may be a clinically meaningful secondary outcome, given 
the often persistent and debilitating social cognition deficits in bipolar 
disorder.44,45 Finally, individual cognitive tests comprising the primary 
composite cognitive outcome should be specified separately as ter-
tiary explorative outcomes. This enables exploratory analyses of the 
profile of the treatment effects to assess which tests (i) respond most 
to the particular treatment and/or (ii) show greatest sensitivity to treat-
ment in particular subgroups. Such insights can provide hypothesis- 
generating evidence which—if confirmed in additional trials with these 
particular measures as primary outcomes—could eventually pave the 
way for more personalized treatments of cognitive impairments.
3.6 | What is a “clinically relevant” cognitive 
improvement?
The lack of consensus on what defines a “clinically relevant” cogni-
tive change is problematic for two reasons. First, such information 
is critical for sample size estimations to ensure adequate statistical 
power for detection of efficacy on the primary outcome. Second, this 
information is relevant for extrapolating the clinical importance of po-
tential treatment effects on cognition. If the treatment goal were to 
correct a deficit, we would anticipate effect sizes equivalent to the 
known deficits. However, smaller treatment effects may also be clini-
cally meaningful—such as an improvement that is half- way towards 
the normal function in healthy age- matched individuals.46
The available evidence so far indicates that it is probably unreal-
istic to expect large effect sizes for treatment effects on cognition. 
A key reason is the well- documented learning or practice effect with 
repeated testing (i.e., nonspecific improvement across all participants), 
which reduces the difference in cognitive change between active and 
control groups and thus the magnitude of the treatment effects. To 
optimize the signal to noise ratio for cognitive change, trials should 
implement parallel equivalent forms of the neuropsychological tests 
for the pre- and post- treatment assessments if available. However, 
since learning effects are almost impossible to eliminate, it is of criti-
cal importance to estimate the “clinically relevant” effect on cognition 
with reference to the cognitive change in the control group rather 
than baseline performance. Given the issue of learning effects, small 
to medium effect sizes for between- group differential change in cog-
nition (such as Cohen’s d of 0.2- 0.4) may arguably represent clinically 
relevant treatment effects. We recommend that all trials also include 
measures of socio- occupational function so that the impact of im-
provement in cognition on day- to- day functioning can be assessed.
3.7 | How should functional implications be 
evaluated?
A major criticism of cognition trials has been that it is unclear from 
change in neuropsychological performance alone whether the treat-
ments actually have real- life benefits for the patients in terms of work 
and social function. It is therefore critical in cognition trials to gain insight 
into the functional implications of potential treatment efficacy on cogni-
tion. Indeed, the Food and Drug Administration (FDA) stipulates that 
cognition trials in schizophrenia must provide evidence for functional 
benefits of cognitive improvement.47 Given this legacy from schizo-
phrenia research, cognition trials in bipolar disorder will need to make 
decisions about how to define their key secondary (if not co- primary) 
measure of functional change. Inclusion of a functional measure would 
also enable assessment of the potential interaction between functional 
status and the cognition benefits of an intervention, which would be 
interesting in light of preliminary evidence for greater treatment- related 
cognitive improvement in high- vs low- functioning patients,48
Two promising existing tools are the observer- based measure, 
the Functional Assessment Short Test (FAST),49 and the performance- 
based test, the Brief University of California, San Diego (UCSD) 
Performance- based Skills Assessment (UPSA- B).50 Both tools are sen-
sitive to functional impairments in bipolar disorder,49,50 and the FAST 
has shown sensitivity to treatment effects.13 The FAST assesses as-
pects of everyday functioning through self- report and clinical obser-
vations, while the UPSA is a performance- based measure of skills (e.g., 
handling finances and planning shopping) associated with functional 
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outcomes. However, these functional measures are not exempt of lim-
itations. While the UPSA- B is available in several languages, it retains 
some transcultural problems. A more general limitation of both mea-
sures is that they do not directly assess patients’ real- world function. 
New virtual reality tools are therefore being developed, including the 
Virtual Reality Functional Capacity Assessment Tool (VRFCAT). This 
tool presents participants with realistic simulated environments to 
recreate daily living activities (e.g., cooking, using public transporta-
tion and food shopping) and seems to be a valid and sensitive assay of 
functional capacity.51 Taken together, the FAST, UPSA- B and VRFCAT 
all seem adequate measures for tracking changes in functional capac-
ity associated with cognitive improvement in bipolar disorder, although 
additional validation data in the disorder are currently a research prior-
ity. Additional “harder measures” of functional capacity, such as occu-
pational and/or academic achievement, should also be assessed since 
some measures may correlate more with cognition or mood symptoms 
than with real- world functioning.
3.8 | When should pre- and post- assessments be 
conducted?
The treatment periods in RCTs targeting cognition range from 1 to 
21 weeks but are most commonly between 6 and 12 weeks.1,16 Short 
study durations have the benefit of limiting the confounding effects 
of mood cycling, whereas longer trial durations may be more likely 
to produce robust and enduring efficacy on cognition and reduce 
potential practice effects. The optimal duration of a particular trial 
would depend on the presumed onset of efficacy for the particular 
intervention based on its putative mechanisms. Specifically, relatively 
pronounced effects may be seen rapidly, depending on the agent. For 
example, a single dose of modafinil was recently found to have acute 
effects on some aspects of cognition in remitted major depressive dis-
order.52 However, a general recommendation would be to administer 
pharmacological and other biological interventions for 6- 12 weeks 
and psychological interventions for 10- 21 weeks, depending on the 
specific treatment program with pre- and post- treatment assessments 
of cognition at baseline and immediately after treatment completion 
(primary time for assessment of efficacy). When possible, a follow- up 
assessment after 3- 6 months would be desirable. This recommenda-
tion is based on (i) the most common practice in RCTs of biological 
and psychological candidate treatments in mood disorders targeting 
mood symptoms or cognitive impairment and (ii) the assumption that 
the functional implications of treatment- related increase in neuro-
plasticity would begin to emerge after 4- 6 weeks and presumably 
increase further with continued treatment.53 The follow- up assess-
ment 3- 6 months after treatment completion would serve to deter-
mine not only whether potential treatment- related cognitive benefits 
persist long- term, but also whether they translate into functional im-
provements, which are likely to occur with a time lag. An analog is the 
typical delay between the physical healing of a sprained ankle and a 
person’s resumption of habitual levels of daily activity and physical 
exercise. It is thus likely that it takes time for objective cognitive im-
provement to translate into better functioning in daily life. Preliminary 
evidence from recent EPO trials supports this notion. Here the ob-
served correlation between EPO- treated patients’ objective cognitive 
improvement and subjective cognitive change in daily life was medi-
ated by change in depressive symptoms in the acute treatment phase 
but was direct 6 weeks after trial completion.15
3.9 | How should “pseudospecificity” be addressed?
Lack of control for changes in mood symptoms in the analysis of 
treatment- associated cognitive change (i.e., the “pseudospecificity” 
issue) is generally problematic in trials of cognition in bipolar disorder 
as some patients may develop mood symptoms during the trial period. 
It is hence important to (i) adjust the analysis of treatment- related cog-
nitive change for symptom fluctuation by covarying for change in mood 
symptoms from baseline to post- treatment at the group level and/or (ii) 
conduct path analysis, which can provide an estimate of whether the 
effects on cognition were direct or simply mediated through symptom 
improvement. In trials aiming to improve mood symptoms as a pri-
mary goal and include cognition as a secondary treatment target, such 
analyses can provide valuable hypothesis- generating evidence for an 
indication for cognitive impairment that may be further explored in a 
subsequent trial with cognition as the primary outcome (as exempli-
fied by the vortioxetine trials in unipolar disorder54). In addition to the 
primary intention- to- treat (ITT) strategy, exploratory post hoc analyses 
can also be conducted to examine whether treatment effects differ be-
tween patients who remain stable throughout the study and patients 
with emerging mood symptoms during the trial.
3.10 | What are the methodological 
recommendations for specific classes of agents?
Some methodological considerations are tied to the properties of 
the particular candidate treatment under investigation, and there-
fore differ between pro- dopaminergic drugs, atypical antipsychotics, 
anti- inflammatory agents, and neuroprotective drugs. In particular, 
drug- specific considerations include decisions about what clinical 
state patients should be in, which secondary cognition outcomes to 
select, whether to use an adjunctive or monotherapy design, which 
comparator to choose (placebo or an active treatment with no known 
effects on cognition), and, for adjunctive studies, which concomitant 
medication to allow. Monotherapy should only be used if the candi-
date cognition treatment under investigation has mood- stabilizing ef-
fects for ethical reasons and to ensure generalizability of the findings. 
Such trials would necessitate an active comparator drug with mood- 
stabilizing effects, since withholding mood- stabilizing treatment from 
patients could trigger new illness episodes.
Pro- dopaminergic drugs such as pramipexole and modafinil should 
be investigated in an adjunctive design given some concern about 
potential risk of mania switch.55,56 Such trials should ideally restrict 
recruitment to euthymic patients, given the antidepressant effects of 
these compounds,57,58 which would confound the interpretation of 
potential cognitive benefits in symptomatic patients. Alternatively, 
they could include depressed patients in a head- to- head adjunctive 
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superiority design with a comparator without pro- cognitive effects, 
although euthymic patients are better to rule out pseudospecificity. 
Preliminary evidence suggests that the cognitive benefits of pramipex-
ole are restricted to strictly euthymic patients.12 It could therefore be 
hypothesized that the cognitive benefits of increasing prefrontal dopa-
mine tonus with pro- dopaminergic drugs may be confined to patients 
with relatively low baseline dopamine tonus (as in euthymia). Given 
the drug effects on dopaminergic neurotransmission, inclusion of a re-
ward processing or emotional decision- making cognition measure as 
a secondary outcome could aid mechanistic insight into the clinical 
effects of the treatment, as illustrated in the pramipexole trial.59
Cognition trials investigating anti- psychotic or antidepressant 
drugs with efficacy on depressive symptoms, such as lurasidone and 
vortioxetine, should include euthymic patients to rule out pseudo-
specificity. Such trials may wish to include an emotional processing 
test as a secondary outcome to assess the mechanisms of treatment 
efficacy on depression. For antidepressants, the trial design should 
be adjunctive and mood state carefully monitored as antidepressant 
monotherapy is not usually recommended in bipolar disorder, given 
concern about potential mania switch in response to vortioxetine.60 In 
contrast, trials investigating anti- inflammatory agents or neuroprotec-
tive drugs (such as EPO) with no documented effects on bipolar de-
pression would arguably benefit from expanding the inclusion criteria 
to partial remission (i.e., allowing for more subsyndromal depressive 
symptoms) in the interest of recruitment feasibility and generalizability 
of the findings. For the same reason, the trial design should be ad-
junctive and involve a placebo control arm. These recommendations 
(i.e., inclusion of partially remitted patients and using an adjunctive 
design with a control group) also apply to psychological interventions 
for cognitive impairment such as cognitive and functional remediation.
3.11 | How should statistical issues around missing 
data be handled?
Strategies for handling missing data differ between cognition trials 
despite the general recognition that intention- to- treat (ITT) analyses 
should be implemented to prevent bias caused by participant drop-
out. However, the definition of ITT is vague and involves several 
approaches for handling missing data in longitudinal trials. Last ob-
servation carried forward (LOCF) is one approach that involves im-
putation of the missing values with the last observed value, assuming 
that the outcomes would be unchanged from the last observed value. 
Although LOCF minimizes the number of participants eliminated from 
the analysis, it has been criticized for underestimating the variability in 
the data, particularly if there is a large amount of missing data. More 
feasible ways to handle missing data with repeated assessments are 
multiple imputation or mixed models, which are more robust and take 
account of missing values, including whether data are missing at ran-
dom, and inter- individual changes over time. These statistical methods 
are increasingly used in clinical research because of their availability in 
many statistical software packages.
In cognition trials, there will often be only two cognition data points 
in the primary analysis (i.e., baseline and post- treatment) to minimize 
learning effects. If the primary outcome is cognitive change from base-
line, inclusion of data from patients with only baseline assessments 
will provide very limited information in the statistical model, adding 
only to the estimation of the between- subject variance in the data. 
The results of the analysis will therefore be highly similar to those of 
a modified ITT analysis, in which data are analyzed for patients with 
both data points. However, mixed models or multiple imputation pro-
cedures are highly feasible for the (secondary) analysis of long- term 
cognitive change that includes more data points. Nevertheless, there 
are no universal standards, as the most appropriate method for han-
dling missing data depends on the goals, endpoints and context of the 
particular trial.
4  | FUTURE PERSPECTIVES
4.1 | Need for insight into the neurobiological 
targets of cognitive enhancement
The FDA Critical Path Initiative has highlighted neuroimaging in 
human populations as a key tool to accelerate the screening and selec-
tion of new candidate central nervous system (CNS) treatments.61 For 
cognition trials, assessment of neuroimaging biomarkers will increase 
insight into the neurobiology of cognitive improvement and thereby 
lead to identification of common biomarkers of pro- cognitive inter-
ventions. Specifically, the application of neuroimaging in cognition 
treatment discovery carries the potential to identify early change in 
key neuronal networks that predicts subsequent cognitive improve-
ment. Detection of such neuro- circuitry target engagement and dose−
response findings could guide the development of new mechanism 
compounds for cognitive impairment as a conceptually important 
middle step between investigation of such treatments in preclinical 
models and large- scale clinical phase III trials. This is in line with the 
National Institutes of Health (NIH) statement around target engage-
ment as a potential regulatory pathway.62 Electrophysiological and 
psychophysiological methods may also aid insight into the neurobio-
logical underpinnings of cognitive impairments and neuronal target 
engagement. In particular, quantitative electroencephalography (EEG) 
seems to provide sensitive biomarkers for cognitive impairments and 
treatment- related cognitive change in neurological disorders63,64 and 
would be interesting to include in trials in bipolar disorder.
Emerging evidence points to aberrant activity in the dorsal pre-
frontal cortex (PFC) and related circuitries as well as failure to sup-
press default mode network (DMN) activity as common neuronal 
correlates of cognitive impairment across distinct neuropsychiatric 
disorders.65-72 In a series of randomized placebo- controlled func-
tional magnetic resonance imaging (fMRI) studies, a single dose of 
EPO and long- term EPO treatment produced target engagement 
in the dorsal PFC and DMN during strategic encoding and work-
ing memory across healthy individuals and patients with affective 
disorders, and this activity change correlated with cognitive im-
provement.73-75 Meta- analytic findings also point to an increase in 
dorsal prefrontal activity as the most reliable marker of cognitive 
improvement in response to cognitive remediation interventions in 
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schizophrenia.76 There is also emerging evidence for structural hip-
pocampal volume increase as a key neurobiological target for cogni-
tion treatments. Indeed, structural MRI assessments of patients with 
affective disorders in the RCTs of long- term EPO vs saline treatment 
revealed increased subregional volume in the left hippocampus in 
EPO- treated patients, which correlated with EPO- related verbal 
memory improvement.77 Similarly, MRI assessment of an RCT of cog-
nitive remediation in schizophrenia showed treatment- associated 
preservation of left hippocampal gray matter volume over 2 years, 
which mediated the improvement of cognition.78 Taken together, 
this emerging neuroimaging evidence points to PFC and DMN tar-
get engagement as well as hippocampal volume increase as potential 
biomarkers for pro- cognitive effects of distinct pharmacological and 
psychological interventions across several psychiatric disorders—
possibilities that warrant investigation in future trials.
Finally, it would also be of key interest to include assessments of 
potential blood- based biomarkers for cognitive improvements in fu-
ture trials, given emerging evidence for a putative role of inflammation 
and oxidative stress in patients’ cognitive deficits.79 Specifically, as-
sessments of changes in such biomarkers early in the course of treat-
ment can lead to identification of markers that predict subsequent 
treatment efficacy on cognition.
TABLE  1 Quick guide with a summary of the International 
Society for Bipolar Disorders (ISBD) Targeting Cognition Task Force 
recommendations
Methodological recommendations for cognition trials in bipolar 
disorder by the International Society for Bipolar Disorders Targeting 
Cognition Task Force: quick guide
How can we enrich trials with cognitively impaired patients?
Assess subjective cognitive difficulties and functional capacity
Screen for cognitive impairment with a brief, feasible neuropsycho-
logical test battery
Two new screening tools for cognitive impairment may be 
particularly feasible: the COBRA (self- report measure) and the 
SCIP (brief neuropsychological test battery)
What is a feasible threshold for cognitive impairment?
≥ 0.5 SD below the normative mean on a short neuropsychological 
screening test or, alternatively, ≥1 SD below the mean on at least 
two single neuropsychological tests
If logistically feasible, cognitive impairment may be established with 
reference to general IQ
Which criteria should be used to select trial participants?
Generally include partially or fully remitted patients in trials where 
cognition is the primary outcome to minimize “pseudospecificity” issues
Exclude patients with a history of moderate or severe brain injury, 
neurological disease, current uncontrolled thyroid condition, 
unstable medical illness, current or recent alcohol and substance use 
disorders, intellectual disability, or ECT within the past 6 months
Allow concomitant medications. These should be carefully recorded 
and, if possible, kept stable
In possible, disallow certain medications (high- dose antipsychotics 
and anticholinergic medications)
Taper benzodiazepines to a maximum dose equivalent to 22.5 mg 
oxazepam/7.5 mg diazepam per day and restrict use of benzodiaz-
epine and other hypnotics 6 hours prior to cognitive testing
Keep serum lithium within the therapeutic range
How should efficacy on cognition be assessed?
In general, select a broad cognitive composite score spanning 
sustained attention, verbal memory, and executive functions as 
the primary outcome
Use tests that are broadly equivalent to those included in the 
ISBD- BANC
Select key cognitive tests of interest and a functional measure as 
secondary outcomes
What is a “clinically relevant” cognitive improvement?
Since learning effects are almost impossible to eliminate, a 
“clinically relevant” effect on cognition should be estimated with 
reference to the cognitive change in the control group
Given the issue with learning effects (which reduce the difference 
between the active and control groups), small to medium effect 
sizes for treatment effects may be considered clinically meaningful
How should functional implications be evaluated?
The FAST, UPSA- B and VRFCAT are among the best measures to 
date for tracking changes in functional capacity associated with 
cognitive improvement in bipolar disorder
When should pre- and post- assessments be conducted?
In general, administer biological interventions for 6- 12 weeks and 
psychological interventions for 10- 21 weeks with pre- and 
post- treatment assessments of cognition at baseline and 
immediately after treatment completion. If feasible, perform 
follow- up assessments after 3- 6 months
Methodological recommendations for cognition trials in bipolar 
disorder by the International Society for Bipolar Disorders Targeting 
Cognition Task Force: quick guide
How should “pseudospecificity” be addressed?
Adjust the statistical analysis of cognitive change for symptom 
fluctuation and conduct path analysis
What are the methodological recommendations for specific classes of 
agents?
Monotherapy should only be used if the candidate treatment has 
mood- stabilizing effects for ethical reasons and to ensure 
generalizability. Use an active comparator drug with mood- 
stabilizing effects.
Cognition trials investigating anti- psychotic, pro- dopaminergic or 
antidepressant drugs with efficacy on depressive symptoms 
should ideally include euthymic patients to rule out pseudospeci-
ficity. Alternatively, they can include depressed patients in a 
head- to- head adjunctive superiority design with a comparator 
without pro- cognitive effects
Trials investigating anti- inflammatory or neuroprotective drugs with 
limited effects on mood would benefit from expanding the 
inclusion criteria to partial remission in the interest of recruitment 
feasibility and generalizability. Use an adjunctive study design with 
a placebo control
How should statistical issues around missing data be handled?
Intention- to- treat analyses should be implemented to prevent bias 
caused by dropout
Feasible ways to handle missing data with repeated assessments 
after treatment start are multiple imputation or mixed models
COBRA, Cognitive Complaints in Bipolar Disorder Rating Assessment; 
ECT, electroconvulsive therapy; FAST, Functional Assessment Short Test; 
SCIP, Screen for Cognitive Impairment in Psychiatry; SD, standard devia-
tion; UPSA- B, Brief UCSD Performance- based Skills Assessment; VRFCAT, 
Virtual Reality Functional Capacity Assessment Tool.
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4.2 | Targeting of treatments according to patients’ 
illness stage
There is increasing evidence for clinical progression in bipolar disor-
der80 and growing consensus that bipolar disorder involves “clinical 
staging,” a progression from prodromal (at- risk) stages to more severe 
and resistant presentations.81,82 In line with the staging model, inter-
ventions seem to have differential efficacy depending on patients’ ill-
ness stage and interventions should therefore be tied to the particular 
illness stage.81,82 Extrapolating from this, inclusion of a heterogeneous 
group of patients at various stages of their illness could potentially 
preclude treatment efficacy on cognition. This raises questions about 
whether future cognition trials should stratify patients for their illness 
stage and, if so, which stages to target with cognition treatment.
In the EPO trials, there was a small but significant increase in 
patients’ chances of achieving treatment efficacy on cognition with 
greater illness chronicity (16% for every year of illness).14 If the finding 
is generalizable, cognition treatments may be more beneficial at later 
illness stages that are accompanied by greater cognitive and functional 
disability. On the other hand, cognitive impairment at later stages may 
be more treatment- resistant and be accompanied by greater functional 
disability, which could have been prevented with an early intervention. 
Indeed, preliminary evidence from a schizophrenia trial suggests that 
cognitive remediation is more effective in younger, less functionally 
impaired patients who use less antipsychotic medication.83 Given the 
paucity of evidence for stage- specific effects on treatment efficacy 
on cognition in bipolar disorder, this question should be addressed in 
future cognition trials.
4.3 | Potential for a multimodal treatment approach
The combination of pharmacological and non- pharmacological (i.e., 
psychological or neurostimulation) interventions is likely to pro-
duce synergistic effects on brain function that translate into more 
robust efficacy on cognition than either treatment modality alone. 
Importantly, the translation of treatment- related cognitive improve-
ment into greater functional capacity in chronically ill patients may 
be more difficult due to fewer environmental opportunities to apply 
regained cognitive skills. In this respect, it may be necessary in chroni-
cally ill patients to apply a multi- modality approach. There is currently 
a paucity of evidence for synergistic effects of multimodal interven-
tions. A recent preclinical study revealed that the EPO- associated in-
crease in hippocampal pyramidal neurons and oligodendrocytes was 
only maintained long- term (≥6 months) in mice that also received 
continuous cognitive challenges.83 This finding is consistent with the 
demonstration in a cognition trial in unipolar depression that work-
ing patients displayed greater cognitive benefits of vortioxetine than 
those who were unemployed.48 Taken together, these observations 
are suggestive of stronger treatment effects on neuroplasticity and 
cognition in individuals who receive continuous cognitive challenges. 
Multimodal treatment approaches should therefore be considered a 
key next step for trials that demonstrate cognitive improvement in 
response to unimodal interventions.
5  | CONCLUSION
This guidance paper from the ISBD Targeting Cognition Task Force 
provides the first broad consensus- based recommendations for future 
cognition trials in bipolar disorder, which may help overcome some 
of the methodological challenges in the field. The recommendations 
are summarized in Table 1. Key recommendations are to enrich tri-
als with cognitively impaired patients by screening them with a brief 
neuropsychological test battery, to generally select a broad cognitive 
composite score as the primary outcome and a functional measure 
and key cognitive tests as secondary outcomes, to include partially 
or fully remitted patients, to exclude patients with current substance 
or alcohol use disorder, to disallow certain non- study medications if 
possible and to keep all other concomitant medication stable. While 
the ideal design will vary to some degree depending on the mecha-
nism being targeted and the hypothesized onset of effects, most 
recommendations are generally applicable for cognition trials in bi-
polar disorder. Following these recommendations will increase the 
internal validity of cognition trials by limiting confounding factors 
and the external validity by ensuring generalizability of the findings 
and assessment of their translation to real- world outcomes. Finally, 
neuroimaging and electrophysiological assessments in future trials 
may identify the neurobiological targets for pro- cognitive interven-
tions that can aid future drug discovery strategies. Studies are also 
warranted to explore the potential synergistic effects of multimodal 
treatment approaches. Implementing the recommendations is likely 
to advance our understanding of which cognition treatments work, 
for whom and why. Specifically, optimizing the trial design and meth-
odology across trials so findings become more replicable and com-
parable will advance the understanding of which treatments do—or 
do not—improve cognition. While the field is still in its infancy, the 
assessment of whether cognition treatments should be targeted to 
particular illness stages will clarify for whom these treatments have 
particular benefits. Finally, neuroimaging and neurophysiological as-
sessments will clarify why certain treatments work by elucidating their 
neurobiological mechanisms.
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